Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
11/2005
11/17/2005US20050257284 Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants
11/17/2005US20050257281 Method for preparing a sterile transgenic fish
11/17/2005US20050257280 Nonhuman model animal nonresponsive to endotoxin and lipoprotein or lipopeptide
11/17/2005US20050257279 Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism
11/17/2005US20050257278 Transgenic non-human animals expressing a truncated activin type II receptor
11/17/2005US20050256304 Modified factor VIII
11/17/2005US20050256303 Having antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity, used as a drug administration carrier
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256301 Pain, stroke, traumatic brain injury, blocking a voltage-sensitive calcium channel, blocking the nicotinic acetylcholine receptor; synthetic, has no free N- or C-terminus, cysteine residues bonded to form a disulfide bond
11/17/2005US20050256300 Method for using a static electric field to induce crystallization and to control crystal form
11/17/2005US20050256299 Vaccines
11/17/2005US20050256075 Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
11/17/2005US20050256070 Adjuvant
11/17/2005US20050256056 Peptide inhibitors of HIV
11/17/2005US20050256054 Drug therapy for celiac sprue
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256052 Isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation; binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256050 Vascular endothelial growth factor 2
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050256046 obtaining a sequence-defined molecular weight markers that provide an accurate and robust calibration set for determinations of molecular weight of production batches; subjecting the molecular weight markers to column chromatography to establish a relationship between retention time and molecular weight
11/17/2005US20050256044 Gastrointestinal proliferative factor and uses thereof
11/17/2005US20050256043 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies
11/17/2005US20050256042 Methods of preventing and treating alimentary mucositis
11/17/2005US20050256041 polypeptides, polynucleotides encoding the polypeptides and antibodies, for detecting ligands, as well as agonists and antagonists, modulation of tumor growth, metastasis and immunology
11/17/2005US20050256039 Novel fibroblast growth factors and methods of use thereof
11/17/2005US20050256036 Gastrointestinal proliferative factor and uses thereof
11/17/2005US20050256035 Ctp-extended erythropoietin
11/17/2005US20050255597 Transformation of cells with vector carrying transgenic virus
11/17/2005US20050255574 Proteins
11/17/2005US20050255573 An in vitro method of maintaining a mouse or human pluripotent cell in a pluripotent state by increasing expression of a gene that encodes a factor which acts intracellularly and maintainspluripotency, where the factor is a polypeptide of the sequence of SEQ ID NO: 4; cultures
11/17/2005US20050255560 Ztnf11, a tumor necrosis factor
11/17/2005US20050255559 Isolated nucleic acid molecule(s) encoding a human calcium sensitive potassium channel subunit protein designated beta2, encoded proteins, and uses thereof
11/17/2005US20050255558 Signal sequence polypeptides for diagnosis, prevention and treatment of metabolic disorders
11/17/2005US20050255557 Novel compounds
11/17/2005US20050255556 Refolding of ion channel proteins
11/17/2005US20050255555 Monoclonal antibody specific to epidermal growth factor receptor for targeting tumors and treating cancer; tissue targeted therapy
11/17/2005US20050255554 Fusion peptides isolatable by phase transition
11/17/2005US20050255553 Mage C2 antigenic peptides and uses thereof
11/17/2005US20050255551 Methods and compositions relating to chimeric nicotinic receptor subunits
11/17/2005US20050255550 Suppression of xenotransplant rejection
11/17/2005US20050255548 Protein scaffolds for antibody mimics and other binding proteins
11/17/2005US20050255547 Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same
11/17/2005US20050255546 DNA coding for a polypeptide; a polymer conjugated drug with increased stability of the protein in vivo; stimulating the production of erythrocyte progenitor cells in culture in the presence of the polypeptide, or in vivo
11/17/2005US20050255545 Regulation of human hematopoietin receptor-like protein
11/17/2005US20050255543 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
11/17/2005US20050255542 Expressing a thioredoxin-fused membrane protein, particularly a G protein-coupled receptor, in a cell-free system that preferably contains a nonionic detergent
11/17/2005US20050255531 Signal transduction
11/17/2005US20050255530 Identification and isolation of pluripotency determining factors
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255513 Regulatable growth of filamentous fungi
11/17/2005US20050255511 Fra-1 expression in brain cancer
11/17/2005US20050255510 Fra-1 expression in brain cancer
11/17/2005US20050255502 Screening agents which modulate formation of FANCD2-containing foci; cell expressing polynucleotide comprising DNA sequence encoding protein
11/17/2005US20050255496 Ztnf12, a tumor necrosis factor
11/17/2005US20050255490 Novel G protein-coupled receptors
11/17/2005US20050255480 A norovirus-permissive cell culture, including dendritic- and macrophage-lineage cells and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway infected with a norovirus
11/17/2005US20050255478 Staphylococcus epidermidis nucleic acids and proteins
11/17/2005US20050255469 Human 5-ht7 receptor promoter sequence
11/17/2005US20050255461 Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E
11/17/2005US20050255460 Detecting presence of human papillomavirus E6 proteins using polypeptide comprising modular protein domains (PDZ); screening for cell proliferative disorders
11/17/2005US20050255457 Nucleic acids encoding mirafiori lettuce virus protein and utilization thereof
11/17/2005US20050255455 Eif4e gene mutations and potyvirus resistance
11/17/2005US20050255452 Using reporter fusions as tools in monitoring protein-protein interactions
11/17/2005US20050255449 Targeted fusion proteins and methods for the characterization of cellular membrane domains
11/17/2005US20050255228 Process for controlling protein to salt ratio in animal muscle protein composition and protein composition
11/17/2005US20050255182 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
11/17/2005US20050255141 Biological scaffolds comprising bone morphogenic protein for use in induction endochondral bone growth and treatment of bone disorders; tissue repair
11/17/2005US20050255125 Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255123 Chimeric ebola virus envelopes and uses therefor
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005US20050255107 Anti-angiogenic proteins and fragments and methods of use thereof
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255100 Isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5; tumor necrosis factor blocking agent; cyclosporine immunosuppressant; antibiotic; anti-inflammatory; graft versus host disease, viral infection, cancer, leukemia, immunodeficiency, autoimmune disorder
11/17/2005US20050255099 Antigenic fusion protein carrying Galalpha 1,3Gal epitopes
11/17/2005US20050255093 treating nervous system disorders induced by stroke or injury, injured by trauma to reduce oxidative stress, administering a conjugate of antioxidant enzyme and a clostridial neurotoxin cell binding domain, and a clostridial neurotoxin translocation domain; tissue-targeted therapy
11/17/2005US20050255089 adeno-associated virus 5 (AAV5) specific polynucleotides, that codes for an AAV5 specific proteins; delivering polynucleotides to cells using the AAV5 vectors and particles
11/17/2005US20050255088 Administering mutant Salmonella sp. for therapy of solid tumor cancer, disrupted msbB gene and is capable of targeting a solid tumor cancer
11/17/2005US20050255087 Adeno-associated virus vectors
11/17/2005US20050255084 Use of a half-transporter protein of the abcg-family for selecting cells and in gene therapy
11/17/2005US20050255083 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005CA2569085A1 Polynucleotides for the detection of escherichia coli
11/17/2005CA2566418A1 Polynucleotides for the detection of staphylococcus aureus
11/17/2005CA2566344A1 Mutant pneumolysin proteins
11/17/2005CA2566195A1 Process for the preparation of doxorubicin conjugates with lactosaminated human albumin and the obtained conjugates
11/17/2005CA2566101A1 Novel soluble cd14 antigen
11/17/2005CA2566041A1 T-type calcium channel splice variant compositions and methods
11/17/2005CA2565731A1 Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
11/17/2005CA2565658A1 Compounds for specific viral target
11/17/2005CA2565227A1 Human complement c3 derivates with cobra venom factor-like function
11/17/2005CA2564769A1 Cellular permissivity factor for viruses, and uses thereof
11/17/2005CA2564202A1 Ammonium/ammonia transporter
11/17/2005CA2563521A1 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
11/17/2005CA2563508A1 Myosin light chain kinase inhibitors and methods of use
11/17/2005CA2563367A1 Novel compositions and methods in cancer
11/17/2005CA2560865A1 Cancer associated antigens
11/17/2005CA2560264A1 Gm1 promoter and use thereof
1 ... 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 ... 2916